RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive cancer that has the highest mortality rate out of all breast cancer subtypes. Conventional clinical treatments targeting ER, PR, and HER2 receptors have been unsuccessful in the treatment of TNBC, which has led to various...

Descripción completa

Detalles Bibliográficos
Autores principales: Haque, Sakib, Cook, Kiri, Sahay, Gaurav, Sun, Conroy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537780/
https://www.ncbi.nlm.nih.gov/pubmed/34683988
http://dx.doi.org/10.3390/pharmaceutics13101694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537780/
https://www.ncbi.nlm.nih.gov/pubmed/34683988
http://dx.doi.org/10.3390/pharmaceutics13101694

Ejemplares similares